美元基金重新“杀”回中国创新药!

动脉网
Nov 05, 2025

2025年9月,恒瑞医药又完成一笔NewCo交易,与美国Braveheart Bio就其自主研发的心肌肌球蛋白小分子抑制剂HRS-1893项目达成独家许可协议,首付款6500万美元,交易总额最高10.13亿美元。值得一提的是,这已经是恒瑞医药今年以来的第四笔BD交易,当前BD交易总额已超过150亿美元。这无疑是一个耀眼的数字,但在大额BD交易频发的当下,其实也并不算新鲜事,反倒是站在后面的出资方更...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10